Factor XI (fXI) is a homodimeric zymogen that is converted to a protease with 1 (1/2-fXIa) or 2 (fXIa) active subunits by factor XIIa (fXIIa) or thrombin. It has been proposed that the dimeric structure is required for normal fXI activation. Consistent with this premise, fXI monomers do not reconstitute fXI-deficient mice in a fXIIa-dependent thrombosis model. FXI activation by fXIIa or thrombin is a slow reaction that can be accelerated by polyanions. Phosphate polymers released from platelets (poly-P) can enhance fXI activation by thrombin and promote fXI autoactivation. Poly-P increased initial rates of fXI activation 30- and 3000-fold for fXIIa and thrombin, respectively. FXI monomers were activated more slowly than dimers by fXIIa in the presence of poly-P. However, this defect was not observed when thrombin was the activating protease, nor during fXI autoactivation. The data suggest that fXIIa and thrombin activate fXI by different mechanisms. FXIIa may activate fXI through a trans-activation mechanism in which the protease binds to 1 subunit of the dimer, while activating the other subunit. For activation by thrombin, or during autoactivation, the data support a cis-activation mechanism in which the activating protease binds to and activates the same fXI subunit.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3650707PMC
http://dx.doi.org/10.1182/blood-2012-12-473629DOI Listing

Publication Analysis

Top Keywords

fxiia thrombin
16
fxi activation
16
fxi
12
dimeric structure
8
fxi monomers
8
activation thrombin
8
fxi autoactivation
8
activating protease
8
autoactivation data
8
activate fxi
8

Similar Publications

Discovery of a new lead molecule to develop a novel class of human factor XIIa inhibitors.

J Thromb Thrombolysis

December 2024

Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA, 70125, USA.

Article Synopsis
  • FXIIa is a plasma protease in the contact activation pathway, and inhibiting it could lead to safer anticoagulation treatments without the bleeding risks of current options.!* -
  • The study tested an amidine-containing molecule (inhibitor 1) and found it primarily inhibits human FXIIa with an IC value of ~30 µM, while showing variable selectivity against other factors involved in blood coagulation.!* -
  • Inhibitor 1 effectively prolongs clotting time in plasma without significant cytotoxicity, making it a promising candidate for further development as a safer anticoagulant for thromboembolic diseases.!*
View Article and Find Full Text PDF

Back to basics: the coagulation pathway.

Blood Res

October 2024

Daisy Hill Hospital, 5 Hospital Road, Newry, BT35 8DR, UK.

The classic coagulation cascade model of intrinsic and extrinsic coagulation pathways, i.e. contact activation pathway and tissue factor pathway, has been widely modified.

View Article and Find Full Text PDF

Synergistic Procoagulant Mechanism and Application of Kaolin-Zeolite Composite Hemostat for Effective Hemorrhage Control.

ACS Appl Mater Interfaces

September 2024

Key Lab of Applied Chemistry of Zhejiang Province, Department of Chemistry, Zhejiang University, Hangzhou 310027, China.

Achieving timely and effective hemorrhage control is imperative for the survival of individuals with severe bleeding. Hemostatic materials, by enhancing the natural cell-based coagulation response, are essential tools in modern and military medical practice for controlling bleeding, especially in emergency and surgical settings. Here, we report a new type of composite hemostatic material with two different aluminosilicate-based components, kaolin and zeolite, which synergistically work together in different stages of the coagulation cascade reactions.

View Article and Find Full Text PDF

Plasma kallikrein (PKa) is an important activator of factor XII (FXII) of the contact pathway of coagulation. Several studies have shown that PKa also possesses procoagulant activity independent of FXII, likely through its ability to directly activate FIX. We evaluated the procoagulant activity of PKa using a mouse whole blood (WB) thrombin-generation (TG) assay.

View Article and Find Full Text PDF

New Triazole-Based Potent Inhibitors of Human Factor XIIa as Anticoagulants.

ACS Omega

March 2024

Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, Louisiana 70125, United States.

Factor XIIa (FXIIa) functions as a plasma serine protease within the contact activation pathway. Various animal models have indicated a substantial role for FXIIa in thromboembolic diseases. Interestingly, individuals and animals with FXII deficiency seem to maintain normal hemostasis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!